The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

ACD440 is a topical gel formulation targeting peripheral neuropathic pain. The substance, a TRPV1 antagonist, shows powerful ...

One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

The MHRA has approved sebetralstat (Ekterly) as the first oral, on-demand treatment for hereditary angioedema (HAE) attacks ...

Seaport Therapeutics has dosed the first patient in its phase 2b BUOY-1 trial of GlyphAllo, a novel oral prodrug of ...

North East and North Cumbria NHS has begun a year-long rollout of the Healthinote digital health platform to support patients ...

Researchers at Imperial College London have discovered that an unusual DNA structure could be key to reversing chemotherapy ...

Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with ...

BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

Proximie has announced a new partnership with HistoSonics to support the rollout of the Edison Histotripsy System across ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Biotech company VarmX has received clearance from the US FDA to begin a phase 3 trial of its lead candidate, VMX-C001, in ...